Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
0.1725
+0.0212 (14.01%)
At close: May 12, 2025, 4:00 PM
0.1650
-0.0075 (-4.35%)
After-hours: May 12, 2025, 7:59 PM EDT
Vor Biopharma Stock Forecast
VOR's stock price has decreased by -89.91% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Vor Biopharma stock have an average target of 7.83, with a low estimate of 3.00 and a high estimate of 14. The average target predicts an increase of 4,439.13% from the current stock price of 0.17.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vor Biopharma stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy → Hold Downgrades $6 | Buy → Hold | Downgrades | $6 | +3,378.26% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 | Buy | Reiterates | $8 | +4,537.68% | Mar 21, 2025 |
| Stifel | Stifel | Strong Buy Maintains $12 → $5 | Strong Buy | Maintains | $12 → $5 | +2,798.55% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $13 | Strong Buy | Maintains | $18 → $13 | +7,436.23% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
n/a
from 258.19M
Revenue Next Year
n/a
EPS This Year
-0.91
from -1.70
EPS Next Year
-0.86
from -0.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 102.2M | ||
| Avg | n/a | n/a | 32.8M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.70 | -0.56 | -0.63 | ||
| Avg | -0.91 | -0.86 | -0.90 | ||
| Low | -1.39 | -1.59 | -1.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.